Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT)
暂无分享,去创建一个
[1] V. Devita. Hodgkin's disease--clinical trials and travails. , 2003, The New England journal of medicine.
[2] P. Maslak,et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] E. Jaffe,et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Connors,et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Zelenetz,et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. , 2001, Blood.
[6] K. Propert,et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.
[7] P. Gobbi,et al. ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] G. Papa,et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] V. Diehl,et al. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. , 2003, Hematology. American Society of Hematology. Education Program.
[10] T. Miller,et al. Low-Dose Involved Field Radiation after Chemotherapy in Advanced Hodgkin Disease: A Southwest Oncology Group Randomized Study , 1994, Annals of Internal Medicine.
[11] R. Fisher,et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Greil,et al. Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG. , 2004 .
[13] P. Davis,et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] K. Naresh,et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Zelenetz,et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy‐proven primary refractory Hodgkin's disease , 2004, British journal of haematology.
[16] A. Hagenbeek,et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Dirk Hasenclever,et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] K. Goodman,et al. Intensity-modulated radiotherapy for lymphoma involving the mediastinum. , 2005, International journal of radiation oncology, biology, physics.
[19] B. Clarkson,et al. Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Friedberg,et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Mauch,et al. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] V. Diehl,et al. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] E. Winer,et al. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. , 1990, International journal of radiation oncology, biology, physics.
[24] A. Zelenetz,et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. , 2004, Blood.
[25] S. Horning,et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] V. Diehl,et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] G. Bonadonna,et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] A. Ng,et al. Controversies in early-stage Hodgkin's disease. , 2002, Oncology.
[29] S. Horning,et al. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival. , 1996, International journal of radiation oncology, biology, physics.
[30] J. Raemaekers,et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. , 2003, The New England journal of medicine.
[31] V. Diehl,et al. Part II: Hodgkin's lymphoma--diagnosis and treatment. , 2004, The Lancet Oncology.
[32] R. Greil,et al. Intensification of Chemotherapy and Concomitant Reduction of Radiotherapy Dose in Intermediate Stage Hodgkin′s Lymphoma: Results of the Fourth Interim Analysis of the HD 11 Trial of the GHSG. , 2004 .
[33] L. Prosnitz,et al. The case for adjuvant radiation therapy in advanced Hodgkin's disease. , 1996, Cancer investigation.